In light of the marked differences in the intrinsic biological underpinnings and prognostic 20 outcomes among different subtypes, Consensus Molecular Subtype (CMS) classification 21 provides a new taxonomy of colorectal cancer (CRC) solely based on transcriptomics data 22 and has been accepted as a standard rule for CRC stratification. Even though CMS was built 23 on highly cancer relevant features, it suffers from limitations in capturing the promiscuous 24 mechanisms in a clinical setting. There are at least two facts about using transcriptomic data for 25 prognosis prediction: the engagement of genes or pathways that execute the clinical response 26 pathway are highly dynamic and interactive with others; and a predefined patient stratification 27 not only largely decrease the statistical analysis power, but also excludes the fact that clusters of 28 patients that confer similar clinical outcomes may or may not overlap with a pre-defined 29 subgrouping. To enable a flexible and prospective stratified exploration, we here present a 30 novel computational framework based on bi-clustering aiming to identify gene regulatory 31 mechanisms associated with various biological, clinical and drug-resistance features, with full 32 recognition of the transiency of transcriptional regulation and complicacies of patients' 33 subgrouping with regards to different biological and clinical settings. Our analysis on multiple 34 large scale CRC transcriptomics data sets using a bi-clustering based formulation suggests 35 that the detected local low rank modules can not only generate new biological understanding 36 coherent to CMS stratification, but also identify predictive markers for prognosis that are 37 general to CRC or CMS dependent, as well as novel alternative drug resistance mechanisms. 38
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INTRODUCTION 45
Colorectal cancer is the fourth most frequent cancer in the United States, which accounts for 46 more than 8% of adult cancer incidence and 8% cancer deaths in 2018 (1). Epidemiology datasuggests the average five-year survival rate of CRC is 64.9%, while more than 80% of 48 patients die from the disease in five years in the case of metastasis (2, 3). Amongst all, 49 intra-tumor heterogeneity could account for a significant part of poor treatment response. 50 CRC is one of the cancer types with most clearly delineated heterogeneity, a few molecular 51 subtyping methods have been developed, with the goal that it will facilitate the translation of 52 molecular subtypes into the clinic (4-12). Among these, the Consensus Molecular Subtype 53 (CMS) classification has been accepted as a standard practice for colorectal cancer (CRC) 54 stratification (4, 5). CMS classification was derived from a cohort of 18 independent gene 55 expression data sets with 4,151 samples of CRC, and it has stratified more than 85% of these 56 CRC samples into four classes with distinct molecular features and prognoses (4). However, 57 to the best of our knowledge, it remains largely undiscovered regarding the CMS class 58 specific prognosis and predictive gene markers and relevant biological underpinnings, and 59 further class based targeted interventions (4). A major challenge for identification of disease 60 subtype specific biomarkers is that the statistical power will be largely reduced once the 61 analysis is restricted to a pre-defined stratification. This preprocessing is only meaningful 62 when the stratification perfectly aligns with the diversity among samples in response to the 63 prospective clinical outcome. Otherwise, the pre-stratification would severely limit our power 64 in identifying novel alternative mechanisms underlying the clinical outcomes. These largely 65 undermine the practicality of the CMS classification, and limited its capacity for clinical 66 
translation. 67 68
It is imperative to develop a framework that enables us to study the possible alternative 69 regulatory mechanisms in cancer in recognition of the patients' heterogeneity. We utilized a 70 non-parametric approach to identify gene expression modules pertinent to sub-populations, 71 namely, bi-clustering. Bi-clustering analysis is a technique to identify gene co-expression 72 structures specific to certain and sometimes to-be-identified subsets of samples (13, 14) . The 73 algorithm outputs data blocks, each containing subset of samples and features in a sub-matrix 74 format, called bi-clusters (BC). We have recently released a new bi-clustering R package 75 QUBIC-R, which enables identification of bi-clusters (BCs) in whole-genome level 76 transcriptomics data set and has been shown to have competitive performance compared with 77 others (15-17). We investigated the identified BCs from a large collection of gene expression 78 data of CRC to: (1) identify potential gene modules specific to a subset of CRC samples; (2) 79 provide a mechanistic interpretation of the CRC subtypes, in retrospective of CMS in 80 particular; and (3) 
RESULTS

106
In this study, we conducted a bi-clustering analysis in multiple large CRC data sets aiming to: 107
(1) generate a comprehensive annotation for the landscape of coherent co-expression modules 108 specific to different subsets of samples; (2) identify CMS class dependent BCs and annotate 109 biological mechanisms of the BCs and CMS class, (3) identify prognosis predictive BC that 110 are CMS class dependent/independent; (4) identify alternative drug resistance mechanisms. 111
By applying our in-house algorithm QUBIC-R on eight colon cancer transcriptomics data sets 112 with 1,440 samples, we have identified ~4,000 significant BCs on average in each data set 113 (Table 1) . Each of the BC is further annotated by its statistical significance, the pathways 114 enriched by its genes, and the associations of its samples with CMS class, clinical features, 115 and patients' survival. 116 117 Figure 1A shows the analysis pipeline of this study. Gene expression profile of each data set is 119 first discretized to a binary matrix in preparation for the bi-clustering analysis. Figure 1B vector, i=1,…,K. Otherwise, the vectors have zero values. In this way, the original m × n 124 gene expression matrix with m genes and n samples is expanded to a Km × n binary matrix, 125 as shown in Figure 1B and detailed in Methods section. Then, submatrices enriched by 1s in 126 the discretized matrix are identified as BCs heuristically. Obviously, small K would blur the 127 variability of gene expression across samples, and large K would severely undercut the power 128 of bi-clustering and result in small "narrow" bi-clusters. We also noticed that the proportion of 129 the largest subtype in CRC is about 1/3, and after testing K=2, 3, 4, and 5, we found that the 130 discretization with K=3 results in largest number of significant associations between BCs and 131 biological and clinical features (see details in Methods and Supplementary Figure S1 of the four associations in the eight data sets, with detailed numbers listed in Table 1 . 188 Complete annotation of the BCs is also provided through GitHub and described in 189 On average, we have seen that 44.7% of the DFS associated and 33.9% of the OS associated 217
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Supplementary
BCs are also associated with at least one CMS class while the rest are CMS classification 218 independent, as shown in Figure 2C , suggesting possible CMS class specific prognosis 219 markers. Most of the CMS dependent DFS associated BCs are associated with CMS class I 220 and IV while some OS associated BCs were found to be independent of the CMS classes.
222
The ratio of BCs that are significantly associated with biological pathways (left), CMS classes 223 (middle) and patient's DFS and OS (right) versus the quantiles of the bi-clustering 224 significance are shown in Figure 2D . Again, we observe that the more significant BCs tend 225 to significantly enrich more biological pathways. Similar patterns are not identified for CMS 226 class in all datasets. This coincides with our initial motivation that: patients stratifications 227
should not be fixed for all the clinical/biological outcomes, as each of them may have 228 different levels of diversity, and even the most cancer relevant stratification, such as CMS, 229 may not perfectly align with the true subtypes with regard to a certain prospective outcome. Among all the DFS/OS associated BCs, the proportion of the BCs (y-axis) that significantly 257 over-represent a (sub)sample class in each dataset (x-axis). In (C), (E) and (F) call this a consensus functional annotation of the BC landscape in CRC. As shown in Figure 3 , 273 49 pathways/gene sets in total are examined, and here is how these pathways were selected. To have an even finer view, we drew pie graphs with sectors of varied radius and shade to 284 provide a more quantitative measure of the intricate relationships among pathways/gene sets 285 and different phenotypes. Each pie graph consists of up to eight sectors, one sector for one 286 dataset, depending on whether DFS or OS data is available for the dataset. The radius of the 287 sector shows the proportion of genes in the pathway that are hit by the BC in the dataset, and 288
shade of the sector shows the significance of the enrichment test for the genes in the BC 289 against the pathway. The larger the radius, the more the genes are being hit the BC; the darker 290 the shade, the more significant the enrichment is. Note that for each pool, only the BC with 291 the highest enrichment significance of the pathway is selected, in drawing the radius and 292
shade of the sectors. Details of the color parameters are shown in Supplementary Note. 293 294
Moreover, to exhibit how similar the 18 different pools or phenotypes are, we regrouped the 295 47 pathways, and found that they in fact fall into 10 categories: BCs of top bi-clustering 296 significance, over-representing CMS I, II, III, IV, unclassified, associated with DFS, 297 associated with DFS in a CMS dependent manner, associated with OS, associated with OS in 298 a CMS dependent manner, as shown on the right of the figure. The re-grouping was done in 299 such a way that each pathway was given a score based on the average radius and shade of the 300 pie graph over all datasets, namely, the hitting frequency and the enrichment significance 301 value, and was then assigned to one of the 10 categories with a highest score. The 10 302 The top of the figure shows 18 different pools that the BCs in each dataset are placed in, and 349
the left of the figure shows the pathways that are consistently enriched by the BCs in the pool. 350 Each pie graph consists of up to eight sectors, one sector for one dataset, depending on 351 whether DFS or OS data is available for the dataset. For each of the 18 pools in each dataset, 352 only the BC with the highest enrichment significance of the pathway is selected, and the level 353 of enrichment is presented by the radius and shade of the sectors: the larger the radius, the 354 more the genes in the corresponding pathway are being hit the BC; the darker the shade, the 355 more significant the enrichment is using genes in the BC for the pathway. On the right, the 356 pathways are re-grouped into 10 categories, so that the pathway is assigned to the group that it 357 most significantly represents.
359
Heterogeneous prognosis of CRC in retrospective of CMS 360
For all the eight data sets, on average 19.2% (12,641/65,744) of the BCs are significantly 361 associated (p<0.005) with at least one of the CMS classes, and among these, the proportion of 362
BCs associated with each class is shown in Figure 2E . On average, BCs associated with at 363 least one CMS class only cover 23.6%, 15.6%, 30.1% and 24.1% of the samples for CMS I-IV, 364 respectively (shown in Supplementary Figure 2) , suggesting that most of the underlying 365 cancer sub-groups may not align perfectly well with the CMS classification. Comparing the 366 proportion of samples in the BCs falling under different CMS class (shown in Figure 2F) , 367 there are relatively more BCs aligning with CMS class I and IV, and unclassified, suggesting Among all the BCs associated with DFS, 42.9% also over-represent certain CMS classes, 376 while this rate is 49.5% for OS (See Figure 2H) It is noteworthy that the T cell and leukocyte activation is a significant OS dependent feature 395 for CMS1 patients but not for other CMS classes (Figure 3) . CMS I has high MSI, mutation 396 load and immune response, associated with higher abundance of neo-antigen and better 397 
response to immune-therapy (4). A high (CD8+) T-cell infiltration and activation in this group
Alternative drug resistance mechanisms of CRC 421
Chemo-therapy is one of the standard cancer treatment methods that induces cell death of fast 422 proliferating cancer cells (20). It has been reported that cancer cells could develop resistance 423 mechanism to chemo-therapy through alterations in pathways including cell proliferation, 424 apoptosis, DNA damage repairing and stress response through changes in expression levels 425 and/or mutation status of key genes (21, 22). Our understanding of drug resistance mechanism 426 is largely complicated by intra-tumor heterogeneity within a tumor tissue and its intricate 427 micro-environmental stresses. It is noteworthy that multiple alternative resistance 428 mechanisms may exist among the patients, where each patient's cancer cells acquiring one or 429 several such mechanisms can suffer from poor prognosis to chemo-therapy. In this study, we 430 attempt to identify the multiple chemo-resistance mechanisms within a heterogeneous patients 431 population by our bi-clustering formulation. We hypothesize that the alternative resistance 432 mechanisms among patients could be reflected by the BCs associated with poor prognosis to a 433 certain chemo-drug.
435
The clinical information in TCGA provides patients' treatment response to three most 436 prevalent CRC chemo-therapy plans, including 5-Fluorouracil (5-FU), Oxaliplatin (OXA), 437 and the combination of OXA, 5-FU and Leucovorin (FOLFOX). We selected those BCs 438 associated with resistances to the three drugs with TCGA expression data. A BC is defined as 439 associated with resistance of a chemo-drug if the following two conditions are both met: (1) 440 among drug treated samples, the overall survival of samples in the BC is significantly worse 441 than those not in the BC (p<0.001); and (2) 
5-FU is one of the most commonly used chemo-drugs in treating CRC (23). We identified 11 458
BCs associated with 5FU resistance. Agglomerative clustering and stepwise test revealed that 459 the 11 BCs form four groups, where each group consists of a number of genes tightly 460 co-expressed, and a number of samples presented with 5FU resistance, as shown in Figure 4A . 461 The first BC group is highly enriched by the genes involved in known chemo-resistance 462 related mechanisms, including over expression of CFLAR involved in apoptosis and FAS OXA is a platinum-based antineoplastic chemo-drug used to treat colorectal cancer (23). We 482 have identified 10 BCs with strong associations to OXA resistance, which were further 483 clustered into three groups as shown in Figure 4B . The first BC group shows an overlap with 484 the first group in 5FU resistance, in that the genes are also involved in known 485 chemo-resistance related mechanisms including CFLAR, CAPRIN2, TYROBP, CLK1, OGT 486 and LTB4R2 as well as SYCE2, RBM6, ZNF638, ZNF169, ZNF26, ZNF333, ZNF493, 487 ZNF234 and ZNF33A related to cell cycle, mRNA processing and DNA binding. Meanwhile, 488 this group also contains overly expressed DNA synthesis and cell cycle genes POLA1, CHFR, 489 and TAF1; mRNA processing gene PCF11; EPHA7 and COL4A3 related to tissue 490 development; and ITPR2 related to calcium dependent signaling transduction. The second 491 group also contains CFLAR, CAPRIN2, SYCE2, and LTB4R2 identified in the first group. In 492 addition, this group also contains cyclin-D binding transcription factor DMTF1; 493 transcriptional regulation co-factor EP300; GTF2H4 related to RNA polymerase II 494 transcription initiation; mRNA splicing gene DDX39B; and cell surface channel, transporter 495 or exchanger genes PKD2, TRAPPC10, SMG1, and TRIO. The third group contains a 496 number of nuclear ribonucleoproteins and HSPA5, where the latter has been previously 497 identified as a chemo-resistance biomarker and molecular target in B-lineage acute 498 lymphoblastic leukemia (32). 499 500
FOLFOX is combinatorial therapy of 5Fu, OXA with Leu--a reduced folic acid based drug 501 that is used in combination with other chemotherapies to enhance effectiveness or prevent 502 side effects of the chemo-drugs (23, 33). We have identified eight BCs forming four BC 503 groups ( Figure 4C) . The first BC group shows strong overlaps with the first group of 5FU 504 chemo-resistance, and the first and second group of OXA chemo-resistance, which includes 505 CFLAR, CAPRIN2, SYCE2, CSAD, MSH5, XPA, OGT, LTB4R2, ZNF234, ZNF169, 506 ZNF493, ZNF26, and ZNF333. The second group is composed of highly expressed JAK2, 507 which is involved in multiple cytokine receptor signaling pathways related to immune 508 response; Rho GTPase Activating Protein DLC1 (tumor suppressor); cell death related genes 509 NME1, BCL2L15 and RPSS3A; tissue development regulating gene FOXA2; TCA cycle and 510 respiration electron transport genes ATP5C1 and COX7A2L; and mitochondrial inner 511 membrane translocase TIMM23. In addition, this group is also highly enriched by overly 512 expressed ribosome proteins. The third group contains highly expressed CAPRIN2, cell 513 proliferation regulating gene DMTF1 and mRNA processing proteins DDX39B and GTF2H4. 514 The fourth group is composed of under expressed microRNA MIR3911 and antisense mRNA 515
EIF1AX-AS1. 516 517
To validate the drug resistance mechanism we identified using BCs, we collected independent 518 datasets of drug screening on colon cancer cell line (see methods). Unfortunately, to the best 519 of our knowledge, 5-FU is the only one drug with a wide spectrum of sensitivity measure on 520 cell lines among the three. 5-FU screening was performed on 29 and 19 colon cancer cell 521 lines for two independent datasets (34, 35). In each dataset, we computed the correlations 522 between the basal level expressions of all the genes and cell's response to 5-FU, measured by 523
IC50 and GI50 (see Supplementary table 5). Distribution of the correlations for genes in each 524
BC group was compared with the distribution of the correlation for all genes, which serves as 525 a random background. Density curves of the correlations of each BC group and the 526 background are shown in Figure 4D and 4E. We have seen that, comparing with the 527 background correlation level, genes in BC group 4 show much higher correlations to cells' 528 resistance to 5-Fu, and BC groups 1-3 also contain a marked portion of genes that are more 529 correlated with 5-Fu resistance than background. This serves as further validation of our 530 observations of alternative drug resistance mechanisms. Detailed lists of the validation data 531 are provided in Supplementary Table 5 . 532 In summary, for each chemo-drug, we have identified a few resistance mechanisms, some of 533 which are novel to CRC, and they are presented in the form of BC groups. It is noteworthy 534 that the genes CFLAR, CAPRIN2, SYCE2, OGT, and LTB4R2 are consistently observed as 535 resistance associated for all the three drugs. Further investigation of the sample distribution of 536 the BC groups suggests that the first BC group of 5-Fu, OXA and the second BC group of 537 FOLFOX highly overlap, which correspond to poor response of 5-Fu and OXA in CMS1 538 samples and FOLFOX in CMS2 samples ( Figure 4F ). The second BC cluster of OXA and the 539 third BC cluster of FOLFOX overlap, which corresponds to poor response in CMS1 samples. classes. In columns 1-3, a "cross" sign indicates the drugs that samples in the BCs show 564 resistance for; in columns 4-6, larger sizes of the sectors indicate higher significances that the 565 BC's resistance mechanisms is also exhibited in CMS I (blue), II (yellow), III (green), and IV 566 (red); in columns 7-10, larger sizes of the squares indicate higher significances that the BC is 567 positively (blue)/negatively (red) enriched by samples in each CMS class (only p<0.001 are 568 shown); the last column shows for each BC, the type of drug and BC group it is linked to. 569 570
Bi-clusters associated with mutations 571
We have also tested the association between BCs and 117 high frequently-mutated and 572 non-MSI-associated genes in TCGA COAD data. has a small number of samples. In such case, the statistical power on each stratified class of 590 samples is largely reduced. Moreover, even though CMS and other cancer subtyping methods 591 have used highly cancer relevant features, when looking at a particular drug response or 592 prognosis, multiple alternative alterations may exist in specific but unknown subset of 593 samples, which may or may not overlap with a certain stratification. In addition, multiple 594 genes may interactively contribute to one response mechanism, which is especially the case in 595 terms of drug resistance markers, as alterations in multiple pathways are always employed in 596 one off-target resistance mechanism (36-38). How alternative drug resistance mechanisms 597 (and their combinations) are correlated with disease subtypes or other clinicopathological 598 features is largely undiscovered. Limiting our analysis into a pre-defining cancer subtyping or 599 signature pathways would be a potential hurdle that could not only be misleading, but also 600 severely harm the statistical power. provides an easily comprehensible way to understand the underlying subtypes, as well as the 611 functional modules being executed in the BC. Our analysis has clearly demonstrated that 612 bi-clustering based approach can effectively identify biomarkers for alternative prognosis 613 related or drug resistance mechanisms from large scale transcriptomics data. We posit that 614 bi-clustering is more sensitive to locate the biomarkers specific to small subset of samples and 615 the inference on the multiple genes in the BC can be provide more biologically coherent 616
interpretations. 617 618
Nonetheless, we have seen a few more challenges that remain to be solved beyond this study: 619
(1) most of current bi-clustering methods tend to exclude the highly overlapping BCs, which 620 may be problematic when consistency of BCs across different datasets are to be performed. 621 This raises a demand for effective identification of bi-clusters with high consistency through 622 different data sets; (2) our current analysis pipeline lacks a predicative model using BCs, 623 which largely limits its potential of practice. A possible solution is to incorporate the 624 bi-clusters with a binary matrix factorization formulation, i.e. treating each BC as a column 625 basis of the discretized data matrix, and the predictive model could be built between an 626 outcome variable and the sets of explanatory variables consisting of the loadings of all the BC 627 bases; (3) it is noteworthy some genes within a prognosis or drug resistance predictive BC are 628 only selected because they are co-expressed (or co-regulated) with the true prognosis or drug 629 resistance associated genes, and the third challenge remains to identify the genes that truly 630 contribute to the poor prognosis or drug resistance that can become possible drug targets; and 631 (4) the BC's statistical significance is estimated by an estimation formula for the upper bound 632 of p value. The current method works well for the BCs with small number of 0s, but an 633 improvement is need for the BCs with low consistency. We fully anticipate these challenges 634 can be solved in future studies to increase the feasibility of BC based biomarker study.
636
Overall, our analysis generated a comprehensive annotation of BC based co-expression 637 modules in CRC that offers novel biological characterizations for CMS classification and 638 brings new insight of disease subtype and drug therapy specific prognosis predictive markers. 639 The analysis procedures including bi-clustering formulation, identification, significance 640 assessment and parameter settings are provided through https://github.com/changwn/BC-CRC, 641 that can be more generally applied in precision medicine study of other disease types. 642 643
METHODS 644
Data collection 645
We have collected transcriptomics data of 1,440 colorectal cancer tissue samples including 646 the one RNA-Seq data from TCGA and seven microarray data sets from GEO database. The 647 micro-array datasets are selected with the following criteria: (1) data are collected by the top 648 10 most frequently utilized human microarray platforms in GEO database; (2) dataset has 649 more than 50 samples; and (3) dataset also provide certain prognostic or clinical outcome 650 information. We use RPKM normalized expression value for RNA-Seq data and RMA 651 normalized expression for microarray data. Detailed data information is provided in Table 2 . 652 The DFS used in this study is defined as starting at primary treatment and stopping at disease 653 relapse or death. Expression of each gene with multiple probes is assessed by expression of 654 the probe with highest mean expression value in each data set. Genes of mean expressions at 655 bottom 30% quantile in each microarray data set, and genes with 0 expression in more than 85% 656 samples in the RNA-Seq data set are removed from the analysis, in order to control the noise 657 of non-or lowly-expressed genes. 658 659 Colon cancer consensus molecular subtype prediction 663 We applied the R package CMSclassifier to predict the CMS classification of each sample in 664 the eight data sets (39), by which each sample will be predicted with four CMS scores 665 representing its similarity to the four CMS classes. One sample is classified to one subtype if 666 its CMS score of the subtype is larger than 0.5 and a sample is considered as with 667 multiple-classification if both top two CMS scores are larger than 0.5 and the difference 668 between the two scores is smaller than 0.1. 669 670
Modeling the regulatory states of gene expressions via data discretization 671
To capture the regulatory states of a gene, we re-format the original expression data matrix 672 into a larger binary matrix. Specifically, for a gene expression data m×n with m genes and n 673 samples, we first generate a K × n binary matrix Y g for each gene g. Km × n binary matrix Km×n and apply our in-house bi-clustering software QUBIC-R to 677 identify the bi-clusters enriched by 1s in Km×n . 678 679
The rationality of this formulation is that each of the bi-cluster identified here corresponds to 680 a group of genes, the expression levels of each of which, are highly consistent over a subset of 681 samples, hence representing a gene co-expression module specific to the subset of samples. It 682 is worth noting that samples in one bi-cluster are highly likely to share similar transcriptional 683 regulatory signals controlling the relevant genes. More discussion about the connection 684 between bi-clusters and gene expression control are available in Supplementary Method. 685 686
To select a proper K, we have generated binary matrices for each data set by using K=2, 3, 4, 687 and 5 and examined the rate of the bi-clusters that are significantly associated with (1) 688 biological pathways, (2) clinical features, and (3) CMS classification, among all the 689 significant bi-clusters identified in each binary matrix. On average, highest rates of significant 690
BCs are achieved when K=3 throughout all the eight data sets (See more details in 691
Supplementary Figure S1 ).
693
Bi-clustering analysis of binary matrices 694 with resistance of a chemo-drug if the following two conditions are both met: (1) among drug 778 treated samples, the overall survival of samples in the collection is significantly worse than 779 those not in the collection (p<0.001); and (2) among samples in the collection, the overall 780 survival of samples that are drug treated is significantly worse than those not treated (p<0.05). 781 The agglomeration is stopped when no clusters could be merged. 782 783
